Home › Companies › SCYX

Scynexis

SCYX Lead: Approved 1 Biotech Distilled article ↓

Infectious Disease Small Molecule

Most recent annual filing: 2026-03-04

Pipeline (4 active programs)

BREXAFEMME

ibrexafungerp

Small Molecule Target: glucan synthase

Vulvovaginal Candidiasis Approved oral GSK

SCY-247

Small Molecule Target: glucan synthase

Invasive Candidiasis Phase 1 oral
Invasive Candidiasis Phase 1 intravenous
Invasive Fungal Infections Preclinical oral

Technology platforms

fungerps

Proprietary antifungal platform comprising a novel class of triterpenoid glucan synthase inhibitors with broad-spectrum activity against Candida, Aspergillus, Pneumocystis, Coccidioides, Histoplasma, Blastomyces genera and mucorales species, including multidrug-resistant strains; focus on difficult-to-treat and drug-resistant fungal infections.

Targets: glucan synthase

Biotech Distilled coverage (1)

2026-06-24 Scynexis, Inc. (SCYX) - Scientific Deep Dive for SCY-770 (ADPKD) and Pipeline Products

Articles open on Substack. Some deep dives are subscriber-only.